CBU
RNAM

CIBC Bancorp USA’s Avidity Biosciences RNAM Stock Holding History

CIBC Bancorp USA’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$474K Buy
+10,871
New +$439K ﹤0.01% 893

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Bancorp USA's RNAM Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Avidity Biosciences (RNAM) in Q3 2025: 10,871 shares worth $474K. The stake represents ﹤0.01% of the portfolio and ranks #893 among its holdings.

272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

  • CIBC Bancorp USA held 10,871 shares of Avidity Biosciences worth $474K as of Q3 2025.
  • Avidity Biosciences was a new CIBC Bancorp USA position in Q3 2025.
  • Avidity Biosciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #893 holding.
  • 272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.